Contact
Please use this form to send email to PR contact of this press release:
FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma
TO:
Please use this form to send email to PR contact of this press release:
FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma
TO: